Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Current Leases (2023 - 2025)

Contineum Therapeutics has reported Current Leases over the past 3 years, most recently at $1.5 million for Q3 2025.

  • Quarterly results put Current Leases at $1.5 million for Q3 2025, up 141.73% from a year ago — trailing twelve months through Sep 2025 was $1.5 million (up 141.73% YoY), and the annual figure for FY2024 was $1.5 million, up 212.93%.
  • Current Leases for Q3 2025 was $1.5 million at Contineum Therapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Current Leases for CTNM hit a ceiling of $1.5 million in Q3 2025 and a floor of $464000.0 in Q4 2023.
  • Median Current Leases over the past 3 years was $1.0 million (2024), compared with a mean of $985375.0.
  • Biggest five-year swings in Current Leases: surged 212.93% in 2024 and later soared 141.73% in 2025.
  • Contineum Therapeutics' Current Leases stood at $464000.0 in 2023, then surged by 212.93% to $1.5 million in 2024, then increased by 1.72% to $1.5 million in 2025.
  • The last three reported values for Current Leases were $1.5 million (Q3 2025), $1.5 million (Q2 2025), and $1.5 million (Q1 2025) per Business Quant data.